Ruxience 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IAIN/0014 
A.5.a - Administrative change - Change in the name 
14/12/2023 
Annex II and 
and/or address of a manufacturer/importer 
responsible for batch release 
PL 
PSUSA/2652/
Periodic Safety Update EU Single assessment - 
22/06/2023 
23/08/2023 
Refer to Scientific conclusions and grounds recommending 
202211 
rituximab 
the variation to terms of the Marketing Authorisation(s)’ for 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
IA/0012 
A.6 - Administrative change - Change in ATC 
12/12/2022 
23/08/2023 
SmPC 
Code/ATC Vet Code 
PSUSA/2652/202211. 
II/0011 
B.I.a.1.e - Change in the manufacturer of AS or of a 
01/09/2022 
23/08/2023 
Annex II 
The section A in Annex II (Manufacturers of the biological 
starting material/reagent/intermediate for AS - The 
change relates to a biological AS or a starting 
material [-] used in the manufacture of a 
biological/immunological product 
active substance and manufacturers responsible for batch 
release) has been updated as follows:  
Pfizer Ireland Pharmaceuticals 
Grange Castle Business Park 
Clondalkin, Dublin 22 
Ireland 
PSUSA/2652/
Periodic Safety Update EU Single assessment - 
23/06/2022 
24/08/2022 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
202111 
rituximab 
the variation to terms of the Marketing Authorisation(s) for 
PSUSA/2652/202111. 
IB/0009 
C.I.11.z - Introduction of, or change(s) to, the 
07/01/2022 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0008 
C.I.2.a - Change in the SPC, Labelling or PL of a 
23/09/2021 
24/08/2022 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
PSUSA/2652/
Periodic Safety Update EU Single assessment - 
24/06/2021 
20/08/2021 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
202011 
rituximab 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/2652/202011. 
IB/0007 
C.I.2.a - Change in the SPC, Labelling or PL of a 
15/04/2021 
20/08/2021 
PL 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0004 
B.II.f.1.b.3 - Stability of FP - Extension of the shelf 
30/07/2020 
20/08/2021 
SmPC 
life of the finished product - After dilution or 
reconstitution (supported by real time data) 
IB/0003/G 
This was an application for a group of variations. 
08/07/2020 
31/07/2020 
SmPC, 
Labelling and 
PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
II/0001 
to extend the validated hold times of the virus 
25/06/2020 
n/a 
retaining filtration (VRF) load and the 
ultrafiltration/diafiltration (UF/DF) load during active 
substance manufacture. 
B.I.a.2.c - Changes in the manufacturing process of 
the AS - The change refers to a [-] substance in the 
manufacture of a biological/immunological substance 
which may have a significant impact on the medicinal 
product and is not related to a protocol 
IA/0002 
B.II.e.3.a - Change in test procedure for the 
29/05/2020 
n/a 
immediate packaging of the finished product - Minor 
changes to an approved test procedure 
Page 4/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
